NEW YORK (GenomeWeb News) – Indian biotech services company Jubilant Biosys has entered a co-marketing agreement with DiscoveRx to screen potential drug compounds, Jubilant said yesterday.

The agreement will enable Jubilant’s pharmaceutical customers to use DiscoveRx services such as the PathHunter and CampHunter cell lines and chemiluminescent detection technology.

The agreement will also allow DiscoveRx to offer screening solutions from India, Jubilant said.

Jubilant Biosys, based in Noida with facilities in Bangalore, is a subsidiary of Jubilant Organsys.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.